Univest
Univest
  • Markets

Lords Mark Industries Share Price Rises 4% in a Relief Rally: UK MHRA Registration, IVD Sales From December 2026, a Stock Under Rs 100 and the Risks Owners Should Weigh

  • October 5, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Lords Mark Industries Share Price Rises 4% in a Relief Rally: UK MHRA Registration, IVD Sales From December 2026, a Stock Under Rs 100 and the Risks Owners Should Weigh

Lords Mark closed Rs 81.47 (+2.57%) on 5 Oct after a 4% intraday jump. UK MHRA registration; IVD sales from Dec 2026. Mcap Rs 3,394 cr; 88% below 52-week high.

Quick Answer

Lords Mark Industries share price rose over 4% during the session on 5 October and closed 2.57% higher at Rs 81.47 after the company said it had received UK MHRA registration for its in-vitro diagnostics (IVD) portfolio, which clears the way for commercial sales in Great Britain from December 2026, two months earlier than planned. The registration covers haematology and clinical chemistry analysers, sample diluents and cleaning agents, and a separate MHRA registration for its AI-powered dialysis range followed on 28 September. The stock is a small-cap under Rs 100 with a market capitalisation near Rs 3,394 crore, still about 88% below its 52-week high of Rs 669.70, so the rally is a relief bounce and not a recovery. Valuation near 43 times earnings, long receivable days and heavy volatility are the main risks for holders.

Lords Mark Industries share price rose more than 4% on Monday, 5 October, as small caps joined the relief rally on Dalal Street. The stock closed at Rs 81.47, up 2.57% from Rs 79.43, after the company announced progress on UK regulatory approvals for its medical diagnostics business.

If you own the stock, or are wondering whether to, this article covers the business update, the MHRA registration and the December IVD launch, the AI dialysis range, the Silvassa expansion, the FY27 revenue target, the small-cap’s market capitalisation and valuation, the 52-week high and price history, promoter selling and the risks. Data is from company disclosures and market reports, and figures differ by provider, so recheck before acting.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Lords Mark Industries Share Price: Snapshot After the Jump
  • The Business Update Behind the Lords Mark Industries Share Price: UK MHRA Registration and the December IVD Launch
  • FY27 Targets and Financials Behind the Lords Mark Industries Share Price
  • Why the Lords Mark Industries Share Price Is 88% Below Its High
  • Risks for Lords Mark Industries Share Price Owners
  • What to Watch Next for the Lords Mark Industries Share Price
  • Conclusion
  • Frequently Asked Questions
    • Why did Lords Mark Industries share price rise on 5 October?
    • What is the MHRA registration?
    • When will Lords Mark start UK IVD sales?
    • What does Lords Mark Industries do?
    • Is the Lords Mark Industries share price a bargain because it is under Rs 100?
    • What is the Lords Mark Industries 52-week high?
    • What are the main risks?
    • Is Lords Mark Industries a good stock to buy now?

Lords Mark Industries Share Price: Snapshot After the Jump

Measure Figure
5 October close Rs 81.47, up 2.57% from Rs 79.43
Intraday move Up more than 4%
Market capitalisation About Rs 3,394 crore
52-week high Rs 669.70, so the stock is about 88% lower
52-week low About Rs 60 to Rs 63
Recent peak in September About Rs 93.45 on 21 September, a 5% upper circuit after a 15% gain in four sessions
Price to earnings About 43 to 47 times, per different providers

The Lords Mark Industries share price is under Rs 100, but a low share price does not mean the company is a bargain, since the market capitalisation is over Rs 3,000 crore.

The Business Update Behind the Lords Mark Industries Share Price: UK MHRA Registration and the December IVD Launch

  1. The UK Medicines and Healthcare Products Regulatory Agency registered Lords Mark Industries as a manufacturer of IVD products on 24 September 2026.
  2. The registration covers haematological cell analysers, clinical chemistry analysers, buffered sample diluents, and cleaning agents for instruments.
  3. It allows commercial sales in Great Britain from December 2026, two months ahead of the earlier plan.
  4. On 28 September the company announced MHRA registration for its AI-powered dialysis range, taking its renal-care ecosystem closer to international markets.
  5. The Silvassa Phase I expansion was completed three months early, with production of 18 new SKUs starting on 11 October and US FDA approval reportedly pending by December 2026.

Regulatory registration is a necessary step, not a sales figure. The company has not disclosed UK orders or revenue from the IVD launch, so the market is pricing the opportunity into the Lords Mark Industries share price and not the results.

Check the Univest Screener for live data on small-cap healthcare stocks

FY27 Targets and Financials Behind the Lords Mark Industries Share Price

Item Figure Note
FY27 revenue target Rs 825 crore from healthcare divisions Management target reported in September
Trailing revenue About Rs 882 crore Per one data provider
Trailing profit About Rs 84.9 crore Providers differ
Return on equity About 11% Low against the valuation
Return on capital employed About 13.4% Modest
Price to book About 3.7 times Book value about Rs 24.4

The company, the listed successor to Kratos Energy & Infrastructure after a reverse merger through the insolvency process, works in diagnostics and MedTech, renewable energy and LED projects, and legacy paper products. That history is why the Lords Mark Industries share price history and financial figures vary so widely across data providers.

Download the Univest iOS App or Univest Android App to track the Lords Mark Industries share price and small caps live.

Why the Lords Mark Industries Share Price Is 88% Below Its High

The Lords Mark Industries share price has fallen roughly 85% over twelve months on most providers, from a peak of Rs 669.70, though the comparison is distorted by the restructuring and the sharp increase in share count and market value after the merger. The point for holders is that the current price is far below the high, and a 4% bounce does not change the trend.

Date Event Price
2 September Trading near Rs 78 to Rs 81 About Rs 81
18 September Rally in progress Rs 89
Around 21 September 5% upper circuit, 15% in four sessions Rs 93.45 high
29 September Pullback About Rs 86
1 October close Prior close before the update Rs 79.43
5 October close Relief rally and UK update Rs 81.47

Risks for Lords Mark Industries Share Price Owners

Valuation: A multiple near 43 times earnings and 3.7 times book value is high for a business with an ROE near 11%, which leaves the Lords Mark Industries share price vulnerable.

Receivables: One data provider flags debtor days of about 341, which ties up cash and raises collection risk.

Promoter selling: A promoter sale of about 1.03 crore shares has been reported, with the date not confirmed here, which can weigh on sentiment.

No sales yet: Registration is not revenue, and UK sales depend on distribution and orders from December.

Volatility: The Lords Mark Industries share price can move 5% or more in a day in either direction, as small caps of this size do.

What to Watch Next for the Lords Mark Industries Share Price

  1. The first UK IVD orders and revenue after December 2026.
  2. Q2 FY27 results, especially receivables and cash flow.
  3. Silvassa production ramp-up from 11 October and the US FDA decision.
  4. Any further promoter share sales or pledge changes.
  5. Whether the stock holds above Rs 79 after the relief rally.

Conclusion

The Lords Mark Industries share price rose over 4% and closed at Rs 81.47 on 5 October after UK MHRA registration brought the IVD launch forward to December 2026. The stock is still about 88% below its 52-week high, valuation is near 43 times earnings, and no UK revenue is disclosed yet, so the rally in the Lords Mark Industries share price is a relief bounce. Consult a SEBI-registered advisor before making any decision.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why did Lords Mark Industries share price rise on 5 October?

Ans. The Lords Mark Industries share price rose over 4% on UK MHRA registration for its IVD portfolio and a relief rally in small caps, closing 2.57% higher at Rs 81.47.

What is the MHRA registration?

Ans. It is registration with the UK Medicines and Healthcare Products Regulatory Agency as a manufacturer of IVD products, dated 24 September 2026, which allows commercial sales in Great Britain.

When will Lords Mark start UK IVD sales?

Ans. From December 2026, two months earlier than the company had planned.

What does Lords Mark Industries do?

Ans. It operates in diagnostics and MedTech, including IVD analysers and AI-powered dialysis, plus renewable energy and LED projects and legacy paper products.

Is the Lords Mark Industries share price a bargain because it is under Rs 100?

Ans. No. A low Lords Mark Industries share price is not low valuation. The market capitalisation is about Rs 3,394 crore and the P/E is near 43 times.

What is the Lords Mark Industries 52-week high?

Ans. The 52-week high of the Lords Mark Industries share price is Rs 669.70 and the low is about Rs 60 to Rs 63, so the stock is about 88% below its high.

What are the main risks?

Ans. High valuation, long receivable days, reported promoter selling, no disclosed UK revenue yet and high small-cap volatility.

Is Lords Mark Industries a good stock to buy now?

Ans. This article does not constitute investment advice. The UK launch is a positive but the stock is volatile and richly valued. Consult a SEBI-registered financial advisor before investing.



Healthcare stocks IVD lords mark industries Lords Mark Share Price MHRA Small Cap Stocks UK Launch
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply